Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization
Pharmaceuticals · 16.07.2026 · 19 (7) · 1097
DOI: 10.3390/ph19071097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 16.07.2026. Verfasst von Xiaoqin Huang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Intramural Research, National Library of Medicine, National Institutes of Health, Bethesda, MD 20892, USA. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, Intramural Research Program of the National Institutes of Health.
Abstract (Originalsprache)
Background
Drug repurposing offers a cost-effective strategy to accelerate therapeutic discovery, but most computational approaches do not model noncoding genetic variation. Because over 90% of genome-wide association study (GWAS) risk variants reside in noncoding regions, linking regulatory variation to therapeutic hypotheses remains a major challenge.
Methods
We developed an integrative deep learning framework that links allele-specific enhancer prediction to candidate therapeutics through two complementary prioritization strategies, a transcription factor (TF)-based and a gene-based approach. We used MCF7-breast cancer context as a proof-of-concept system.
Results
GWAS heritability was significantly enriched in MCF7 enhancers. Allele-specific variant scoring identified 1537 breast cancer risk variants with strong predicted regulatory effects, and attribution-based motif discovery revealed enrichment of FOXA1-associated motif features, consistent with FOXA1 upregulation in primary tumors. TF-based prioritization, integrating FOXA1 knockdown-induced and drug-induced gene expression profiles, identified 63 candidate compounds, including 18 approved drugs, and recovered fulvestrant, an established breast cancer therapy. Gene-based prioritization, mapping candidate regulatory variants to 347 target genes, identified 140 candidate compounds, including approved breast cancer drugs toremifene and raloxifene. Both strategies identified compounds with anti-correlated transcriptional signatures across core breast cancer hallmark pathways, and integration of pathway anti-correlation, drug-gene interactions, and supporting experimental or clinical evidence yielded 15 high-confidence repurposing candidates.
Conclusions
Recovery of approved breast cancer therapeutics supports the biological relevance of deep learning-predicted regulatory variants. This study establishes a regulatory variant-guided drug repurposing framework that connects noncoding genetic variation to candidate therapeutics and provides a scalable strategy for generating pharmacologically relevant hypotheses from the noncoding genome.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Intramural Research, National Library of Medicine, National Institutes of Health, Bethesda, MD 20892, USA.
Förderung
- Intramural NIH HHS
- Intramural Research Program of the National Institutes of Health
Zitieren
APA
Huang, X., & Ovcharenko, I. (2026). Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization. Pharmaceuticals, 19(7), 1097. https://doi.org/10.3390/ph19071097
Vancouver
Huang X, Ovcharenko I. Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization. Pharmaceuticals. 2026;19(7):1097. doi:10.3390/ph19071097
BibTeX
@article{Huang2026,
author = {Huang, Xiaoqin and Ovcharenko, Ivan},
title = {Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {7},
pages = {1097},
doi = {10.3390/ph19071097}
}
EUVIMED